CSL's R&D Day "Uninspiring," Jarden Research Says

MT Newswires Live10-25

Biotech company CSL (ASX:CSL) hosted a Research and Development (R&D) Day for fiscal 2025, which Jarden Research found "uninspiring," with mixed outcomes across various products, the investment advisory firm said in an Oct. 22 note.

While none of the developments were particularly significant, Jarden said the mix of outcomes for the R&D Day was "uncharacteristic" for the company, with newer, more positive projects focusing on label extensions on approved drugs and early-stage novel projects.

Horizon 2 is the most exciting project in the company's R&D pipeline, but the pathway to US Food and Drug Administration approval remains unclear, Jarden said.

The investment firm kept its AU$329.62 price target and overweight rating on CSL.

Price (AUD): $294.51, Change: $+0.94, Percent Change: +0.32%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478468766?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478468766","market":"sh","top_or_hot":-1,"title":"CSL's R&D Day \"Uninspiring,\" Jarden Research Says","media":"MT Newswires Live","content":"<html><body><p> Biotech company CSL (ASX:CSL) hosted a Research and Development (R&amp;D) Day for fiscal 2025, which Jarden Research found \"uninspiring,\" with mixed outcomes across various products, the investment advisory firm said in an Oct. 22 note.</p><p>While none of the developments were particularly significant, Jarden said the mix of outcomes for the R&amp;D Day was \"uncharacteristic\" for the company, with newer, more positive projects focusing on label extensions on approved drugs and early-stage novel projects.</p><p>Horizon 2 is the most exciting project in the company's R&amp;D pipeline, but the pathway to US Food and Drug Administration approval remains unclear, Jarden said.</p><p>The investment firm kept its AU$329.62 price target and overweight rating on CSL.</p><p>Price (AUD): $294.51, Change: $+0.94, Percent Change: +0.32%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL's R&D Day \"Uninspiring,\" Jarden Research Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL's R&D Day \"Uninspiring,\" Jarden Research Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech company CSL (ASX:CSL) hosted a Research and Development (R&D) Day for fiscal 2025, which Jarden Research found \"uninspiring,\" with mixed outcomes across various products, the investment ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0728928796.USD","symbol_name":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2478468766","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478468766","pubTimestamp":1729822473,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biotech company CSL  hosted a Research and Development (R&D) Day for fiscal 2025, which Jarden Research found \"uninspiring,\" with mixed outcomes across various products, the investment advisory firm said in an Oct. 22 note.While none of the developments were particularly significant, Jarden said the mix of outcomes for the R&D Day was \"uncharacteristic\" for the company, with newer, more positive projects focusing on label extensions on approved drugs and early-stage novel projects.Horizon 2 is the most exciting project in the company's R&D pipeline, but the pathway to US Food and Drug Administration approval remains unclear, Jarden said.The investment firm kept its AU$329.62 price target and overweight rating on CSL.Price : $294.51, Change: $+0.94, Percent Change: +0.32%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","CSL":"卡莱尔伙伴","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7511":"ESG概念","BK7501":"新冠治疗股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","CSL.AU":"CSL LIMITED","BK7508":"医药生物股","AUD":"Audacy Inc.","BK4086":"建筑产品","BK7067":"生物科技","BK4125":"广播"},"translate_title":"Jarden Research表示CSL的研发日“平淡无奇”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"CSL":1,"CSL.AU":1},"content_text":"Biotech company CSL (ASX:CSL) hosted a Research and Development (R&D) Day for fiscal 2025, which Jarden Research found \"uninspiring,\" with mixed outcomes across various products, the investment advisory firm said in an Oct. 22 note.While none of the developments were particularly significant, Jarden said the mix of outcomes for the R&D Day was \"uncharacteristic\" for the company, with newer, more positive projects focusing on label extensions on approved drugs and early-stage novel projects.Horizon 2 is the most exciting project in the company's R&D pipeline, but the pathway to US Food and Drug Administration approval remains unclear, Jarden said.The investment firm kept its AU$329.62 price target and overweight rating on CSL.Price (AUD): $294.51, Change: $+0.94, Percent Change: +0.32%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478468766"}